Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study to Assess the Tolerability, Pharmacokinetics, and Pharmacodynamics of APD791 Administered to Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Feb 2008
Price :
$35
*
At a glance
- Drugs Temanogrel (Primary)
- Indications Arterial thrombosis; Thrombosis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Arena Pharmaceuticals
- 09 Jan 2008 Status changed from recruiting to completed, in accordance with media release 9084166.
- 09 Jan 2008 Results reported by Arena Pharmaceuticals.
- 18 Jul 2007 Status changed from planning to recruiting.